Article
Osimertinib for EGFR-mutant lung cancer with central nervous system metastases: a meta-analysis and systematic review.
Annals of palliative medicine - 1 Sept 2020
Wang Na, Zhang Yaozhong, Mi Yuan, Deng Haowen, Chen Ge, Tang Zilong, Mao Junjie, Cui Saijin, Zhang Yaling, Wang Lei
Abstract excerpt
BACKGROUND: Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), is the only Food and Drug Administration-approved third-generation epidermal growth factor receptor (EGFR)TKI. Osimertinib is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Osimertinib is used to treat a certain type of non-small cell lung cancer. We review some of the main challenges in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.